Quick Answer
Radiopharm Theranostics Ltd reported Total Assets of $86.48 million for fiscal year 2025.
Radiopharm Theranostics Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Assets | $86.48M +20.1% |
$72.04M | — |
| R&D Expense | $27.52M +19.2% |
$23.09M +2.0% |
$22.63M |
| Gross Profit | $39.3K -86.9% |
$299.2K +2.3% |
$292.4K |
- Radiopharm Theranostics Ltd reported Total Assets of $86.48 million for fiscal year 2025.
- Radiopharm Theranostics Ltd showed an increase of +20.1% in Total Assets compared to the prior fiscal year.
- Radiopharm Theranostics Ltd reported R&D Expense of $27.52 million for fiscal year 2025.
- Radiopharm Theranostics Ltd showed an increase of +19.2% in R&D Expense compared to the prior fiscal year.
- Radiopharm Theranostics Ltd reported Gross Profit of $39.3 thousand for fiscal year 2025.
- Radiopharm Theranostics Ltd showed a decrease of -86.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: